Get the Stockscreener App
16.66
1.77%
-0.30
After Hours:
16.62
-0.04
-0.24%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $16.66, with a volume of 8.68M.
It is down -1.77% in the last 24 hours and up +4.58% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$16.96
Open:
$16.94
24h Volume:
8.68M
Relative Volume:
0.81
Market Cap:
$19.40B
Revenue:
$14.57B
Net Income/Loss:
$-296.50M
P/E Ratio:
-64.32
EPS:
-0.259
Net Cash Flow:
$1.64B
1W Performance:
+2.97%
1M Performance:
+4.58%
6M Performance:
+32.22%
1Y Performance:
+79.91%
1-Day Range:
$16.43
$16.94
1-Week Range:
$16.27
$17.16
52-Week Range:
$8.625
$17.53
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
16.66 | 19.75B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
16.75 | 53.59B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.75 | 43.33B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.24 | 40.35B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.10 | 31.98B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
554.34 | 23.93B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Upgrade | UBS | Neutral → Buy |
| Jan-16-26 | Upgrade | Argus | Hold → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-15-25 | Initiated | Truist | Buy |
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - The Motley Fool
Should Viatris’ Japan IgA Nephropathy Win and New Loan Shape VTRS Investors’ Next Move? - Yahoo Finance
Viatris Q1 2026 slides: earnings beat drives shares higher - Investing.com
Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results - Yahoo Finance
Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now - Insider Monkey
Viatris stock hits 52-week high at $16.63 - Investing.com
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris Inc. Class Action: The Gross Law Firm Reminds Viatris In - GuruFocus
VTRS Stock Price and Chart — NASDAQ:VTRS - TradingView
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
A Look at Viatris Inc (VTRS) After 3.1% Gain -- GF Value $11.02 vs Price $16.70 - GuruFocus
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Viatris (VTRS) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Viatris Refinances $247.7 Million Term Loan - Moomoo
VTRSViatris Inc Dividends - Finviz
Form 4 Viatris Inc For: 1 July By Investing.com - Investing.com Canada
Viatris (VTRS) director David S. Simmons granted 2,362 deferred stock units as fees - Stock Titan
Viatris (VTRS) director takes 2,756 deferred stock units instead of cash fees - Stock Titan
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Viatris to Report Second-Quarter 2026 Financial Results on Augus - GuruFocus
ViatrisEnters Amended And Restated Term Loan Credit Agreement On July 1, 2026SEC Filing - TradingView
Viatris Secures ¥40 Billion Three-Year Term Loan With Mizuho to Refinance 2021 Facility - TradingView
Viatris (NASDAQ: VTRS) signs ¥40B three-year unsecured term loan deal - Stock Titan
Viatris Inc Enters Into Amended and Restated Term Loan Credit Agreement for JPY 40,000,000,000 Senior Unsecured Term Loan Facility - marketscreener.com
Lost Money on Viatris Inc. (VTRS)? Join Class Action Before June 3, 2025Contact Levi & Korsinsky - The National Law Review
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026 - BioSpace
The Bull Case For Viatris (VTRS) Could Change Following Positive Japan Phase 3 Data For VR-205 - simplywall.st
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Securities Fraud Class Action Filed Against Viatris Inc. (VTRS) Levi & Korsinsky Reminds Investors of June 3, 2025 - The National Law Review
Viatris reports positive phase 3 results for IgAN drug in Japan By Investing.com - Investing.com India
(VTRS) Risk Channels and Responsive Allocation - Stock Traders Daily
How is Viatris’ stock performance compared to other healthcare stocks? - MSN
Viatris reports positive Japanese phase 3 results for Nefecon in IgAN - MSN
Viatris reports positive phase 3 results for IgAN drug in Japan - Investing.com South Africa
Viatris' VR-205 Meets Primary, Key Secondary Endpoints in Japanese Phase 3 Trial in Kidney Disease - marketscreener.com
Viatris (VTRS) Reports Positive Phase 3 Trial Results for VR-205 - GuruFocus
Viatris kidney drug VR-205 cut protein in urine 33.75% in Japan - Stock Titan
Viatris Inc. (VTRS) Stock Analysis: Exploring a 9% Upside Potential Amid Diverse Healthcare Offerings - DirectorsTalk Interviews
Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy - PR Newswire
Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – VTRS - The National Law Review
Viatris Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationVTRS - The National Law Review
VTRS LAWSUIT ALERT: Levi & Korsinsky Notifies Viatris Inc. InvestorsLead Plaintiff Deadline June 3, 2025 - The National Law Review
Join Class Action to Recover Losses from Viatris Inc. (VTRS)Contact Levi & Korsinsky Before June 3, 2025 - The National Law Review
Enterprise value to EBITDA forward of Viatris Inc. – NASDAQ:VTRS - TradingView
Viatris interim CFO Paul Campbell sells $809,784 in stock By Investing.com - Investing.com South Africa
Viatris interim CFO Paul Campbell sells $809,784 in stock - Investing.com UK
Form 4 Viatris Inc For: 26 June By Investing.com - Investing.com South Africa
Enterprise value to revenue forward of Viatris Inc. – NASDAQ:VTRS - TradingView
Price to earnings forward of Viatris Inc. – NASDAQ:VTRS - TradingView
Enterprise value to EBIT forward of Viatris Inc. – NASDAQ:VTRS - TradingView
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
1.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):